Plain-English translation of NCT06350825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a combination approach—using medications like docetaxel, abiraterone, apalutamide, darolutamide, or enzalutamide along with surgical removal of the prostate—can help men with advanced prostate cancer live longer and healthier lives. Researchers want to see if removing the primary tumor in addition to systemic therapy provides a benefit compared to medication alone.
When prostate cancer spreads to distant sites like lymph nodes, bones, or other organs, doctors typically treat it with medications. However, it's unclear whether removing the original prostate gland can improve outcomes, so this trial is designed to answer that important clinical question.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive systemic therapy (medication) either as a doublet or triplet regimen. You will then be randomly assigned to either have surgery to remove your prostate gland (or brachytherapy) in addition to the medication, or to continue with medication alone. Throughout the trial, you will have regular visits for imaging scans, blood tests, and follow-up appointments to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China